Alexander Barron
Principal Scientist II Novartis AG
Dr. Alex Barron is an immunologist and stromal cell biologist with over 20 years of experience. He currently leads a team at Novartis focused on discovering novel targets and developing therapies for fibrotic diseases. His work includes cross-organ fibrosis target prioritization through human-in-the-loop artificial intelligence and in vitro modeling. Passionate about mentorship, Dr. Barron also dedicates time to guiding the next generation of scientists. He has coauthored 19 publications spanning autoimmunity, viral immunology, stromal biology, and animal models.
Seminars
Wednesday 2nd December 2026
Putting AI on the Bench for Cross-Organ Fibrosis Drug Development
1:30 pm
- Evaluating the rationale for artificial intelligence (AI)-enabled pan-fibrotic development approaches
- Discussing failures and successes of human-in-the-loop AI to prioritize cross-organ fibrosis drug targets and patient-relevant wet lab target validation at scale
Wednesday 2nd December 2026
Panel Discussion: Defining Cross-Indication Expansion Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies
2:30 pm
- Determining when preclinical evidence is sufficiently robust to justify expanding an antifibrotic program into additional fibrotic indications rather than remaining disease-specific
- Identifying the biological, translational, regulatory, and commercial factors that should guide indication prioritization, including shared mechanisms, biomarker availability, clinical endpoints, and unmet need
- Exploring whether future antifibrotic programs should be intentionally designed as multi-indication assets from discovery or whether expansion should remain a staged, indication-by-indication strategy
